We serve Chemical Name:5-methoxy-2,3-dihydro-1H-inden-1-amine CAS:52372-95-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-methoxy-2,3-dihydro-1H-inden-1-amine
CAS.NO:52372-95-9
Synonyms:5-Methoxy-1-indanamine;2,3-Dihydro-5-methoxy-1H-inden-1-amine;1H-Inden-1-amine, 2,3-dihydro-5-methoxy-;5-methoxy-2,3-dihydro-1H-inden-1-amine
Molecular Formula:C10H13NO
Molecular Weight:163.216
HS Code:2922199090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:279.0±40.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.562
PSA:35.25000
Exact Mass:163.099716
LogP:1.53
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-Methoxy-1-indanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-methoxy-2,3-dihydro-1H-inden-1-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1H-Inden-1-amine, 2,3-dihydro-5-methoxy- Use and application,5-methoxy-2,3-dihydro-1H-inden-1-amine technical grade,usp/ep/jp grade.
Related News: The victim — who died Saturday — was a 44-year-Chinese man who flew in from Wuhan in January. 5-methoxy-2,3-dihydro-1H-inden-1-amine manufacturer Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules. 5-methoxy-2,3-dihydro-1H-inden-1-amine supplier The victim — who died Saturday — was a 44-year-Chinese man who flew in from Wuhan in January. 5-methoxy-2,3-dihydro-1H-inden-1-amine vendor Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 5-methoxy-2,3-dihydro-1H-inden-1-amine factory Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly.
